OVERSEAS

📅 Upcoming

🕒 Recent(90d)

News

• Earnings roundup: Lilly’s unwavering momentum, Novartis’ rebound and GSK’s waiting game
  Lilly’s better-than-expected results allayed concerns — for now — over GLP-1 pricing pressure. Elsewhere, Novartis withstood a tumultuous quarter and GSK battled investor angst.
  biopharma_dive · 2h ago
• Chutes & Ladders—Lilly unifies global markets as 36-year vet Patrik Jonsson retires
  Lilly will unite its U.S. and international commercial units as a long-time exec retires. Enanta's CEO will hang up his hat after 23 year at the helm. Estrella has tapped a new a CEO to lead it thr…
  fiercebiotech · 22h ago
• Lilly can’t stop, won’t stop as revenue climbs 39% thanks to GLP-1 bestsellers
  Eli Lilly’s shares rose 4% in early morning trading after reporting revenue of $24.4 billion, well past consensus estimates.
  biospace · 1d ago
• Biotechs going to market alone must learn to go global
  Drug developers increasingly have the option of seeking regulatory approval and commercializing a medicine themselves, rather than accepting an early exit offer. Doing so requires a worldwide strat…
  biospace · 2d ago
• As H-1B visa changes keep coming, biopharmas adjust hiring approach
  The $100,000 H-1B visa fee has significantly affected who biopharma companies hire, according to two experts. It’s not the only program adjustment affecting foreign-born job seekers’ odds of workin…
  biospace · 8d ago
• STAT+: Launch prices for new medicines dipped slightly last year but remain high, analysis finds
  The median net price for 202 newly launched medicines rose by 35%, to $257,000 last year from $173,000 in 2022.
  stat · 10d ago
• Antheia gets $80M conditional DOD loan to onshore to the US
  Biosynthesis manufacturer Antheia has won a conditional loan of $80 million from the US Department of Defense to help boost the domestic production of generic drugs. "Over time, we aim to manufactu…
  endpoints · 10d ago
• Sanofi breaks ground on insulin plant after securing German government support
  The European Commission approved Germany’s financial support after assessing the risks of Sanofi stopping insulin API production at the Frankfurt campus.
  biospace · 10d ago
• STAT+: Pharmalittle: We’re reading about Roche investments in Germany, a Gilead bowel disease drug, and more
  Roche is reviewing all future investments in Germany over health care cost-cutting ​policies, with a top executive citing a loss of trust
  stat · 11d ago
• STAT+: Up and down the ladder: The latest comings and goings
  From new hires to departures, promotions and transfers, here are the latest comings and goings in the pharmaceutical industry.
  stat · 13d ago